<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01566266</url>
  </required_header>
  <id_info>
    <org_study_id>METC 12-3-011</org_study_id>
    <nct_id>NCT01566266</nct_id>
  </id_info>
  <brief_title>Gut Flora and Lipid Metabolism</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well known that metabolic responses to diet and drugs are affected by genetic and&#xD;
      environmental factors. Still, a large part of differences in responses between individuals&#xD;
      remains unexplained. To increase our understanding of individual differences, more and more&#xD;
      attention is paid to the role of intestinal microbiota. Not only energy and glucose may be&#xD;
      related to the microbiota, but also lipid metabolism. This is not surprising as lipid&#xD;
      metabolism, glucose metabolism, and obesity are closely linked.&#xD;
&#xD;
      There is substantial evidence from in particular animal studies that the gut microbiota is&#xD;
      related to lipid and lipoprotein metabolism. However, there is less evidence to what extent&#xD;
      modulation of the gut microbiota changes lipid and lipoprotein metabolism in humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>Measure change between day 1 and day 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism</measure>
    <time_frame>Measure change between day 1 and day 8 (HDL-cholesterol, triglycerides)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>Measure change between day 1 and day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Amoxicillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>2 capsules of 250mg, 3 times per day during 1 week</description>
    <arm_group_label>Amoxicillin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>2 capsules of 250mg, 3 times per day during 1 week</description>
    <arm_group_label>Placebo capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged between 18-70 years&#xD;
&#xD;
          -  serum total cholesterol: 5-8mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  serum triacylglycerol &gt; 3.0mmol/L&#xD;
&#xD;
          -  use of oral anticonceptives&#xD;
&#xD;
          -  pregnant or breastfeeding women&#xD;
&#xD;
          -  kidney insufficiencies&#xD;
&#xD;
          -  unstable body weight&#xD;
&#xD;
          -  allergy to antibiotics&#xD;
&#xD;
          -  treatment with cholesterol-lowering drugs&#xD;
&#xD;
          -  use of medication or a medically prescribed diet&#xD;
&#xD;
          -  active cardiovascular disease&#xD;
&#xD;
          -  abuse of drugs&#xD;
&#xD;
          -  more than 21 alcohol consumptions per week for men and 14 consumptions for women&#xD;
&#xD;
          -  use of an investigational product within the previous 30 days&#xD;
&#xD;
          -  not willing to stop the consumption of products rich in plant stanol or sterol esters&#xD;
             3 weeks before start of the study&#xD;
&#xD;
          -  use of gastric acid inhibitors, laxantia, prebiotica, probiotica and antibiotica for&#xD;
             at least one month before the start of the study and during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Mensink, Prof. Dr. Ir.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>March 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2012</study_first_posted>
  <last_update_submitted>May 13, 2013</last_update_submitted>
  <last_update_submitted_qc>May 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gut flora</keyword>
  <keyword>antibiotics</keyword>
  <keyword>lipid metabolism</keyword>
  <keyword>LDL cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

